The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Benzodiazepines: Risks and benefits. A reconsideration
Open accessAbstract
Over the last decade there have been further developments in our knowledge of the risks and benefits of benzodiazepines, and of the risks and benefits of alternatives to benzodiazepines. Representatives drawn from the Psychopharmacology Special Interest Group of the Royal College of Psychiatrists and the British Association for Psychopharmacology together examined these developments, and have provided this joint statement with recommendations for clinical practice. The working group was mindful of widespread concerns about benzodiazepines and related anxiolytic and hypnotic drugs. The group believes that whenever benzodiazepines are prescribed, the potential for dependence or other harmful effects must be considered. However, the group also believes that the risks of dependence associated with long-term use should be balanced against the benefits that in many cases follow from the short or intermittent use of benzodiazepines and the risk of the underlying conditions for which treatment is being provided.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“They have been shown to be effective in the acute treatment of generalized anxiety disorder, social anxiety, panic disorder, and insomnia [8].”
Citations
Cites
Wilson, S., Nutt, D., Alford, C., Argyropoulos, S., Baldwin, D., Bateson, A., Britton, T., Crowe, C., Dijk, D.-J., Espie, C., et al. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110379307 · Cited by 634
Self-citationBaldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R. T., den Boer, J. A., Fineberg, N. A., Knapp, M., Scott, J., et al. (2005) · Journal of Psychopharmacology · doi:10.1177/0269881105059253 · Cited by 617
Self-citationLingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
Self-citationDell’osso, B., & Lader, M. (2013) · European Psychiatry · doi:10.1016/j.eurpsy.2011.11.003 · Cited by 210
Uncritical positive regard? Issues in the efficacy and safety of psychotherapy
Nutt, D. J., & Sharpe, M. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107086283 · Cited by 123
Self-citationSubstitution therapy for alcoholism: time for a reappraisal?
Chick, J., & Nutt, D. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881111408463 · Cited by 80
Self-citationNeuropharmacology of Benzodiazepines
Stephens, D., & King, S. L. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-398335-0.00059-5 · Cited by 2
Self-citation
Cited by
Sorted by citations
Treatment of Benzodiazepine Dependence
Soyka, M. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1611832 · Cited by 465
Kurko, T., Saastamoinen, L., Tähkäpää, S.-M., Tuulio‐Henriksson, A., Taiminen, T. J., Tiihonen, J., Airaksinen, M., & Hietala, J. A. (2015) · European Psychiatry · doi:10.1016/j.eurpsy.2015.09.003 · Cited by 283
Rogers, J. P., Oldham, C. M., Fricchione, G. L., Northoff, G., Wilson, J. E., Mann, S. C., Francis, A., Wieck, A., Wachtel, L. E., Lewis, G., et al. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231158232 · Cited by 277
Self-citationPolypharmacy Management in Older Patients
Hoel, R. W., Connolly, R. M. G., & Takahashi, P. Y. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.06.012 · Cited by 235
Sequential drug treatment algorithm for agitation and aggression in Alzheimer’s and mixed dementia
Davies, S., Burhan, A. M., Kim, D., Gerretsen, P., Graff‐Guerrero, A., Woo, V. L., Kumar, S., Colman, S., Pollock, B. G., Mulsant, B. H., et al. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117744996 · Cited by 150
Self-citationPharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users
Baandrup, L., Ebdrup, B. H., Rasmussen, J. Ø., Lindschou, J., Gluud, C., & Glenthøj, B. Y. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011481.pub2 · Cited by 128
Bushnell, G., Stürmer, T., Gaynes, B. N., Pate, V., & Miller, M. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.1273 · Cited by 114
Relationship between concomitant benzodiazepine-opioid use and adverse outcomes among US veterans
Gressler, L. E., Martin, B. C., Hudson, T. J., & Painter, J. T. (2017) · Pain · doi:10.1097/j.pain.0000000000001111 · Cited by 109
Marsden, J., White, M., Annand, F., Burkinshaw, P., Carville, S., Eastwood, B., Kelleher, M., Knight, J., O'Connor, R., Tran, A., et al. (2019) · The Lancet Psychiatry · doi:10.1016/s2215-0366(19)30331-1 · Cited by 106
The reappraisal of benzodiazepines in the treatment of anxiety and related disorders
Starcevic, V. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.963057 · Cited by 90
Dopaminergic control of anxiety in young and aged zebrafish
Kacprzak, V., Patel, N. A., Riley, E., Yu, L., Yeh, J.-R. J., & Zhdanova, I. V. (2017) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2017.01.005 · Cited by 88
Patel, M. X., Sethi, F. N., Barnes, T. R., Dix, R., Dratcu, L., Foex, B. A., Garriga, M., Haste, J. C., Kahl, K. G., Lingford-Hughes, A. R., et al. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118776738 · Cited by 82
Pharmacological treatment for generalized anxiety disorder in adults: an update
Reinhold, J. A., & Rickels, K. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1059424 · Cited by 88
Stein, D. J. (2015) · Advances in Therapy · doi:10.1007/s12325-015-0176-6 · Cited by 88
GABAA receptor subtypes and benzodiazepine use, misuse, and abuse
Engin, E. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1060949 · Cited by 83
Luta, X., Bagnoud, C., Lambiris, M. J., Decollogny, A., Eggli, Y., Pogam, M. L., Marques-Vidal, P. M., & Marti, J. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-031156 · Cited by 75
Karsten, J., Hagenauw, L. A., Kamphuis, J., & Lancel, M. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881116681399 · Cited by 79
Kurko, T., Saastamoinen, L., Tuulio‐Henriksson, A., Taiminen, T. J., Tiihonen, J., Airaksinen, M., & Hietala, J. A. (2018) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4551 · Cited by 73
Withdrawing Benzodiazepines in Patients With Anxiety Disorders
Lader, M., & Kyriacou, A. (2016) · Current Psychiatry Reports · doi:10.1007/s11920-015-0642-5 · Cited by 67
Realising the therapeutic potential of neuroactive steroid modulators of the GABAA receptor
Belelli, D., Hogenkamp, D., Gee, K. W., & Lambert, J. J. (2020) · Neurobiology of Stress · doi:10.1016/j.ynstr.2019.100207 · Cited by 67
Pharmacological Treatment of Generalised Anxiety Disorder: Current Practice and Future Directions
Fagan, H. A., & Baldwin, D. S. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2211767 · Cited by 82
Self-citationFiorillo, A., Dell’Osso, B. M., Albert, U., Atti, A. R., Carmassi, C., Carrà, G., Cosci, F., Vecchio, V. D., Nicola, M. D., Ferrari, S., et al. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s83130 · Cited by 69
Examining racial/ethnic differences in patterns of benzodiazepine prescription and misuse
Cook, B., Creedon, T., Wang, Y., Lu, C., Carson, N., Jules, P., Lee, E., & Alegría, M. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.02.011 · Cited by 60
Chapoutot, M., Peter-Derex, L., Bastuji, H., Leslie, W., Schoendorff, B., Heinzer, R., Siclari, F., Nicolas, A., Lemoine, P., Higgins, S., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph181910222 · Cited by 59
“They have been shown to be effective in the acute treatment of generalized anxiety disorder, social anxiety, panic disorder, and insomnia [8].”
BackgroundBegum, M., González‐Chica, D. A., Bernardo, C., Woods, A., & Stocks, N. (2021) · British Journal of General Practice · doi:10.3399/bjgp.2021.0054 · Cited by 59
Baldwin, D. S., den Boer, J. A., Lyndon, G. J., Emir, B., Schweizer, E. E., & Haswell, H. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881115598411 · Cited by 60
Self-citationGrigoriadis, S., Graves, L. E., Peer, M., Mamisashvili, L., Ruthirakuhan, M. T., Chan, P., Hennawy, M., Parikh, S., Vigod, S. N., Dennis, C., et al. (2020) · The Canadian Journal of Psychiatry · doi:10.1177/0706743720904860 · Cited by 61
Recent Development of Nano-Carbon Material in Pharmaceutical Application: A Review
Jiwanti, P. K., Wardhana, B. Y., Sutanto, L. G., Dewi, D. M. M., Putri, I. Z. D., & Savitri, I. N. I. (2022) · Molecules · doi:10.3390/molecules27217578 · Cited by 52
Clonazepam: Indications, Side Effects, and Potential for Nonmedical Use
Dokkedal‐Silva, V., Berro, L. F., Galduróz, J. C. F., Tufik, S. B., & Andersen, M. L. (2019) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000227 · Cited by 53
Understanding the effects of chronic benzodiazepine use in depression: a focus on neuropharmacology
Lim, B., Sproule, B. A., Zahra, Z., Sunderji, N., Kennedy, S. H., & Rizvi, S. J. (2020) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000316 · Cited by 50
Patterns of benzodiazepines use in primary care adults with anxiety disorders
Bernard, M.-M. T., Luc, M., Carrier, J., Fournier, L., Duhoux, A., Côté, É., Lessard, O., Gibeault, C., Bocti, C., & Roberge, P. (2018) · Heliyon · doi:10.1016/j.heliyon.2018.e00688 · Cited by 54
Baandrup, L., Glenthoj, B. Y., & Jennum, P. (2016) · Psychiatry Research · doi:10.1016/j.psychres.2016.04.031 · Cited by 44
Local GABAA Receptor-Mediated Suppression of Dopamine Release within the Nucleus Accumbens
Brodnik, Z. D., Batra, A., Oleson, E. B., & España, R. A. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00268 · Cited by 44
Baandrup, L., Lindschou, J., Winkel, P., Gluud, C. N., & Glenthoj, B. Y. (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2015.1048725 · Cited by 42
Long-term use of benzodiazepines in older patients in Germany: a retrospective analysis
Jacob, L., Rapp, M. A., & Kostev, K. (2017) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125317696454 · Cited by 41
Davies, S. J., Rudoler, D., de Oliveira, C., Huang, A., Kurdyak, P., & Iaboni, A. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211069096 · Cited by 32
Self-citationFaccini, M., Leone, R., Opri, S., Casari, R., Resentera, C., Morbioli, L., Conforti, A., & Lugoboni, F. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116647505 · Cited by 37
Schelp, S. A., Brodnik, Z. D., Rakowski, D. R., Pultorak, K. J., Sambells, A. T., España, R. A., & Oleson, E. B. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.241802 · Cited by 37
Baldwin, D. S., Hou, R. H., Gordon, R., Huneke, N. T. M., & Garner, M. J. (2017) · CNS Drugs · doi:10.1007/s40263-017-0423-2 · Cited by 40
Self-citationSustained Use of Benzodiazepines and Escalation to High Doses in a Canadian Population
Alessi‐Severini, S., Bolton, J. M., Enns, M. W., Dahl, M. E., Chateau, D. G., Collins, D. M., & Sareen, J. (2016) · Psychiatric Services · doi:10.1176/appi.ps.201500380 · Cited by 34
Taurine Protects from Pentylenetetrazole-Induced Behavioral and Neurochemical Changes in Zebrafish
Fontana, B. D., Ziani, P. R., Canzian, J., Mezzomo, N. J., Müller, T. E., dos Santos, M. M., Loro, V. L., Barbosa, N. V., Mello, C. F., & Rosemberg, D. B. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1107-8 · Cited by 34
Radojčić, M. R., Marroun, H. E., Miljković, B., Stricker, B. H. C., Jaddoe, V. W. V., Verhulst, F. C., White, T. J. H., & Tiemeier, H. W. (2017) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2017.02.005 · Cited by 33
Relating neurosteroid modulation of inhibitory neurotransmission to behaviour
Belelli, D., Phillips, G., Atack, J. R., & Lambert, J. J. (2021) · Journal of Neuroendocrinology · doi:10.1111/jne.13045 · Cited by 32
Mokhar, A., Tillenburg, N., Dirmaier, J., Kühn, S., Härter, M. C., & Verthein, U. (2018) · PeerJ · doi:10.7717/peerj.4614 · Cited by 33
Benzodiazepines in anxiety disorders: Reassessment of usefulness and safety
Rickels, K., & Moeller, H. J. (2019) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2018.1500031 · Cited by 30
Pesic, M., Stöhr, T., Ossig, J., Borkett, K., Donsbach, M., Dao, V.-A., Webster, L., & Schippers, F. (2020) · Drugs in R&D · doi:10.1007/s40268-020-00317-0 · Cited by 32
Yeh, W., Lu, S., Wu, M., Lee, K., Chien, C., Fong, Y.-O., Li, K., Lai, Y.-L., Lin, C.-J., Li, Y., et al. (2021) · Sleep Medicine · doi:10.1016/j.sleep.2021.02.056 · Cited by 31
Davies, S., Jacob, B. J., Rudoler, D., Zaheer, J., de Oliveira, C., & Kurdyak, P. A. (2017) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125317743651 · Cited by 30
Self-citationClinical management of withdrawal from benzodiazepine anxiolytic and hypnotic medications
Baldwin, D. S. (2022) · Addiction · doi:10.1111/add.15695 · Cited by 28
Self-citationSleep quality among psychiatry residents
Carvalho Aguiar Melo, M., das Chagas Medeiros, F., Meireles Sales de Bruin, V., Pinheiro Santana, J. A., Bastos Lima, A., & De Francesco Daher, E. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743715620410 · Cited by 28
Initiation and long‐term use of benzodiazepines and Z‐drugs in bipolar disorder
Wingård, L., Taipale, H. T., Reutfors, J., Westerlund, A., Bodén, R., Tiihonen, J., Tanskanen, A. J., & Andersen, M. T. (2018) · Bipolar Disorders · doi:10.1111/bdi.12626 · Cited by 35
High-dose lormetazepam dependence: strange case of Dr. Jekyll and Mr. Hyde
Faccini, M., Tamburin, S., Casari, R., Morbioli, L., & Lugoboni, F. (2019) · Internal and Emergency Medicine · doi:10.1007/s11739-019-02101-8 · Cited by 26
Ahmadi, M., Khalili, H., Abbasian, L., & Ghaeli, P. (2017) · Annals of Pharmacotherapy · doi:10.1177/1060028017696105 · Cited by 26
Lynch, T., Ryan, C., & Cadogan, C. A. (2022) · Health Expectations · doi:10.1111/hex.13392 · Cited by 24
Pétein, C., Spinewine, A., & Henrard, S. (2021) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253211011874 · Cited by 25
Baandrup, L., Fasmer, O. B., Glenthoj, B. Y., & Jennum, P. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-1062-8 · Cited by 25
Heteromeric GABA A receptor structures in positively-modulated active statesPreprint
Miller, P. S., Masiulis, S., Malinauskas, T., Kotecha, A., Rao, S., Chavali, S., Colibus, L. D., Pardon, E., Hannan, S. B., Scott, S., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/338343 · Cited by 25
López‐Pelayo, H., Coma, A. V., Gual, A., Zara, C., & Lligoña, A. (2019) · European Addiction Research · doi:10.1159/000502518 · Cited by 23
Stelmaszczyk, P., Kwaczyński, K., Rudnicki, K., Skrzypek, S., Wietecha‐Posłuszny, R., & Półtorak, Ł. (2023) · Microchimica Acta · doi:10.1007/s00604-023-05739-6 · Cited by 23
Bergstrand, M. P., Beck, O., & Helander, A. (2018) · Clinical mass spectrometry · doi:10.1016/j.clinms.2018.08.004 · Cited by 23
Thronson, L. R., & Pagalilauan, G. L. (2014) · Medical Clinics of North America · doi:10.1016/j.mcna.2014.06.001 · Cited by 24
Discontinuation of Chronic Benzodiazepine Use Among Adults in the United States
Gerlach, L. B., Strominger, J., Kim, H. M., & Maust, D. T. (2019) · Journal of General Internal Medicine · doi:10.1007/s11606-019-05098-0 · Cited by 22
Morera, A. M., Fernández-López, L., & Abreu-González, P. (2020) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2020.107994 · Cited by 22
Wang, S., Kim, J.-B., Sakong, J. K., Suh, H.-S., Oh, K., Woo, J., Yoo, S.-W., Lee, S. M., Lee, S.-Y., Lim, S.-W., et al. (2016) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2016.14.2.177 · Cited by 22
Puzyrenko, A., Wang, D., Schneider, R., Wallace, G. L., Schreiber, S. J., Brandt, K., & Gunsolus, I. L. (2021) · Journal of Analytical Toxicology · doi:10.1093/jat/bkab108 · Cited by 21
Alcohol-medication interactions: A systematic review and meta-analysis of placebo-controlled trials
Traccis, F., Presciuttini, R., Pani, P. P., Sinclair, J., Leggio, L., & Agabio, R. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.11.019 · Cited by 23
Syunyakov, T., & Незнамов, Г. Г. (2016) · Terapevticheskii arkhiv · doi:10.17116/terarkh201688873-86 · Cited by 20
Outpatient benzodiazepine utilization in Croatia: drug use or misuse
Aždajić, M. D., Likić, R., Aždajić, S., Šitum, M., Lovrić, I., & Štimac, D. (2019) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-019-00915-2 · Cited by 20
Chandler, A., Whittaker, A., Williams, N., McGorm, K. J., Cunningham‐Burley, S., & Mathews, G. (2014) · Drugs Education Prevention and Policy · doi:10.3109/09687637.2014.930814 · Cited by 20
Szepietowski, J. C., & Reszke, R. (2016) · Current problems in dermatology · doi:10.1159/000446055 · Cited by 20
Sundseth, A. C., Gjelstad, S., Straand, J., & Rosvold, E. O. (2018) · Scandinavian Journal of Primary Health Care · doi:10.1080/02813432.2018.1459164 · Cited by 19
Calixto, E. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.11.021 · Cited by 19
Li, Z.-L., Zhang, Z.-Y., Zhao, T., Chun-yan, M., Zhang, Q., & Wang, M. (2020) · Microchimica Acta · doi:10.1007/s00604-020-04517-y · Cited by 19
Morton, E. E., & Murray, G. (2019) · Current Opinion in Psychology · doi:10.1016/j.copsyc.2019.08.022 · Cited by 19
Pradhan, A. K., Neumüller, T., Klug, C., Fuchs, S., Schlegel, M., Ballmann, M., Tartler, K. J., Pianos, A., Garcia, M. S., Lière, P., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02630-z · Cited by 19
Bojanić, I. (2024) · Depression and Anxiety · doi:10.1155/2024/5448587 · Cited by 18
Martins, M. L., Pinheiro, E. F., Saito, G. A., Lima, C. A. C. D., Leão, L. K. R., Batista, E. D. J. O., Passos, A. D. C. F., Gouvêia, A., Oliveira, K. R. H. M., & Herculano, A. M. (2024) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2024.1464992 · Cited by 18
Blockade of NOP receptor modulates anxiety-related behaviors in mice exposed to inescapable stress
Silva, A. I., Holanda, V. A. D., Neto, J. A., Silva, E. D., Soares-Rachetti, V. D. P., Calò, G., Ruzza, C., & Gavioli, E. C. (2020) · Psychopharmacology · doi:10.1007/s00213-020-05487-y · Cited by 17
Latent state–trait and latent growth curve modeling of inhibitory control.
Faßbender, K., Meyhöfer, I., & Ettinger, U. (2023) · Journal of Experimental Psychology General · doi:10.1037/xge0001344 · Cited by 17
Intravenous valproate in the treatment of acute manic episode in bipolar disorder: A review
Fontana, E., Mandolini, G. M., Delvecchio, G., Bressi, C., Soares, J. C., & Brambilla, P. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.08.071 · Cited by 14
Hashimoto, T., Shiina, A., Hasegawa, T., Kimura, H., Oda, Y., Niitsu, T., Ishikawa, M., Tachibana, M., Muneoka, K. T., Matsuki, S., et al. (2016) · Annals of General Psychiatry · doi:10.1186/s12991-016-0115-1 · Cited by 13
Lugoboni, F., Mirijello, A., Morbioli, L., Arzenton, E., Leone, R., Faccini, M., Casari, R., Cosmo, S. D., Gasbarrini, A., & Addolorato, G. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1457646 · Cited by 13
Anxiety disorders, post-traumatic stress disorder, and obsessive–compulsive disorder
Gordon, R. P., Brandish, E. K., & Baldwin, D. S. (2016) · Medicine · doi:10.1016/j.mpmed.2016.08.010 · Cited by 14
Self-citationLee, S.-H., Jeon, S. W., Shin, C., Pae, C.-U., Patkar, A. A., Masand, P. S., An, H., & Han, C. (2022) · Psychiatry Investigation · doi:10.30773/pi.2021.0368 · Cited by 12
Peritogiannis, V., Manthopoulou, T., & Mavreas, V. G. (2016) · Journal of Neurosciences in Rural Practice · doi:10.4103/0976-3147.196447 · Cited by 12
Role of Melatonin in the Management of Substance Addiction: A Systematic Review
Das, A., Prithviraj, M., & Mohanraj, P. S. (2022) · Cureus · doi:10.7759/cureus.26764 · Cited by 11
Preclinical pharmacological profiles of vornorexant, a novel potent dual orexin receptor antagonist
Hikichi, H., Tokumaru, Y., Taruta, A., Konno, Y., Karasawa, J.-I., Fukumoto, K., Marumo, T., Fujii, Y., Takahashi, T., Yoshimizu, T., et al. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103624 · Cited by 11
Atchison, K., Watt, J. A., Ewert, D., Toohey, A. M., Ismail, Z., & Goodarzi, Z. (2022) · Age and Ageing · doi:10.1093/ageing/afac195 · Cited by 11
Ceuterick, M., Ngoc, P. V., Bracke, P., & Scholtes, B. (2023) · Social Science & Medicine · doi:10.1016/j.socscimed.2023.116358 · Cited by 11
Oddoux, S., Violette, P., Cornet, J., Akkoyun-Farinez, J., Besnier, M., Noël, A., & Rouillon, F. (2022) · Nutrients · doi:10.3390/nu14122425 · Cited by 11
van der Hoek, H., Peersmann, S. H. M., Maurice‐Stam, H., Kaspers, G. J. L., van den Bergh, E. M. M., Tissing, W. J. E., Kremer, L. C. M., Abbink, F. C. H., de Vries, A. C. H., Loonen, J. J., et al. (2025) · Cancer · doi:10.1002/cncr.35796 · Cited by 10
Paterson, A., Khundakar, M., Young, A., Ling, J., Chakraborty, S. P., Rathbone, A. P., Watson, S., Donaldson, T., & Anderson, K. N. (2021) · BJPsych Bulletin · doi:10.1192/bjb.2021.41 · Cited by 10
The pharmacological management of anxiety disorders
Bleakley, S., & Davies, S. J. (2014) · Progress in Neurology and Psychiatry · doi:10.1002/pnp.357 · Cited by 10
Self-citationPharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users
Baandrup, L., Ebdrup, B. H., Lindschou, J., Gluud, C. N., & Glenthoj, B. Y. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011481 · Cited by 10
Understanding adverse drug reactions: An overview
Greener, M. (2014) · Nurse Prescribing · doi:10.12968/npre.2014.12.4.189 · Cited by 10
Dependence on benzodiazepines in patients with panic disorder: A cross‐sectional study
Fujii, K., Uchida, H., Suzuki, T., & Mimura, M. (2014) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12203 · Cited by 10
A systematic review of treatments for sleepwalking: 100 years of case studies
Stallman, H. M., & Kohler, M. J. (2016) · Sleep and Hypnosis · doi:10.5350/sleep.hypn.2016.18.0118 · Cited by 9
Benzodiazepines May Be Worse Than Opioids
Gauntlett‐Gilbert, J., Gavriloff, D., & Brook, P. (2015) · Clinical Journal of Pain · doi:10.1097/ajp.0000000000000253 · Cited by 10
Machado‐Alba, J. E., Álzate-Carvajal, V., & Jiménez-Canizales, C. E. (2015) · Revista Colombiana de Psiquiatría · doi:10.1016/j.rcp.2015.01.007 · Cited by 9
Varma, S. (2016) · Medicine · doi:10.1016/j.mpmed.2016.09.019 · Cited by 9
Metadata
- Authors
- Baldwin, D. S., Aitchison, K., Bateson, A., Curran, H. V., Davies, S., Leonard, B., Nutt, D. J., Stephens, D. N., & Wilson, S.
- Affiliations
- University of Southampton (GB)
- University of Alberta (CA)
- Ross University School of Medicine (BB)
- University College London (GB)
- Centre for Addiction and Mental Health (CA)
- Ollscoil na Gaillimhe – University of Galway (IE)
- Imperial College London (GB)
- University of Sussex (GB)
- Corresponding author
- Baldwin, David S
- ORCID
- Venue
- Journal of Psychopharmacology
- Publisher
- SAGE Publications
- Published
- 2013-09-24
- Volume
- 27
- Issue
- 11
- Pages
- 967-971
- ISSN
- 0269-8811 (ISSN-L)
- 1461-7285
- OpenAlex
- W2116273170
- Cited by
- 249
- References
- 7
- Citations by year
- 2026: 17 · 2025: 19 · 2024: 14 · 2023: 21 · 2022: 21 · 2021: 22 · 2020: 23 · 2019: 21 · 2018: 21 · 2017: 19 · 2016: 19 · 2015: 16 · 2014: 15
- FWCI
- 22.52
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Locations
- Journal of Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- ePrints Soton (University of Southampton) (acceptedVersion)
- Research Bank (Australian Catholic University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- benzodiazepines, anxiolytics, hypnotics, benzodiazepine dependence, long-term benzodiazepine use, benefits and risks, clinical guidelines, anxiety disorders, insomnia
- MeSH terms
- Benzodiazepines, Humans, Hypnotics and Sedatives, Practice Guidelines as Topic, Risk Assessment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
